Contineum Therapeutics Q2 net loss narrows to $15.2 million from $16.0 million
Contineum Therapeutics reported second-quarter 2026 results on July 30, 2026, showing a net loss of $15.2 million, down from $16.0 million a year earlier. Research and development expenses fell 10 percent to $12.7 million, while general and administrative expenses rose 23 percent to $4.7 million. The company said it has a limited workforce reduction in research and its cash runway extends through mid-2029, which is relevant to shareholders because the company reported no revenue and relies on its cash balance to fund trials.
Key points
- Net loss of $15.2 million, or $(0.40) per share, for the three months ended June 30, 2026, versus $16.0 million, or $(0.62) per share, a year earlier
- Cash, cash equivalents and marketable securities of $236.6 million as of June 30, 2026, with cash runway projected through mid-2029
- Limited workforce reduction in research, including Chief Scientific Officer Daniel Lorrain, as the company streamlines discovery programs
- PROPEL-IPF Phase 2 trial of PIPE-791 has more than 55 sites online in eight countries
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.